2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory

AbbVie expects Skyrizi and Rinvoq to exceed $31.0B combined sales in 2026 (a year ahead of schedule) and retains a strong Botox franchise; it is highlighted as a Dividend King with 50+ consecutive annual payout increases, making it a defensive income candidate. Amgen, despite Prolia losing exclusivity, benefits from Tezspire and Repatha sales and has MariTide (a GLP-1) in Phase 3 targeting the weight-loss market; Amgen has raised dividends annually since initiating them in 2011. The article positions both names as stable, lower-volatility picks amid tech-led weakness and recession concerns—supportive for investor demand but unlikely to trigger large, immediate price moves.

Analysis

Healthcare’s defensive bid now is not only about steady end-market demand but about cash-flow optionality: companies with predictable biologic cash flows can fund buybacks and optional M&A without taking on meaningful balance-sheet risk. That favors firms with near-term, high-margin biologics and established manufacturing scale versus those facing large, near-dated exclusivity events; contract manufacturers and specialty CDMOs are an overlooked second-order beneficiary if biologic production stays concentrated.

Key catalysts to watch are binary and calendarized: clinical readouts and phase transitions (months–18 months) that reset growth optionality, and policy/regulatory shifts (12–36 months) that can compress realized prices across portfolios. Short-term technical flows (risk-off into dividend ETFs) can buoy multiples even where fundamentals are stable, but a deeper recession or accelerated Medicare pricing actions would re-rate defensives quickly.

Relative positioning should prefer balance-sheet optionality and shorter visibility into revenue replacement; that makes certain immunology/neurology-focused franchises more defensible than single-product biologics with near-term generic incursions. Expect a modest dispersion trade: defensive names with higher buyback flexibility to outperform peers exposed to biosimilar risk by mid- to late-2026.

The consensus is underweighting crowding risk in dividend strategies — inflows can create a short-term “safe-haven” premium that unwinds rapidly when liquidity normalizes. That means use income to lower net entry cost rather than as justification for concentrated long-duration exposure; hedge discrete downside around key readouts and policy windows rather than assume immunity to macro stress.

Key Decisions for Investors

• Core long ABBV (12-month horizon): accumulate size in 3 tranches over 6 weeks to average in; target 12-month total return 12–18% with downside risk ~-10% in a deep recession. Use a 10% hard stop or hedge with 6–9 month 7–9% OTM puts if position size >3% NAV.
• Relative pair (6–12 months): long ABBV / short AMGN equal notional to express preference for greater cash-flow optionality. Expect ABBV to outperform by 8–12% if no adverse policy shocks; cut pair if performance dispersion stays <2% after 60 days or if AMGN reports a positive phase-3 surprise.
• Income-overlay on ABBV (3–6 months): sell 3–6 month covered calls 4–8% OTM to harvest elevated dividend carry and reduce basis; alternatively sell cash-secured puts 6–10% OTM to collect premium targeting lower effective entry. Cap upside at the short-strike; maintain a buy-write if implied vol subsidizes premium >2% of position value per month.
• Event hedge for AMGN (9–12 months): buy a limited-cost put spread (e.g., 9–12 month 12/20% OTM) sized to protect core exposure through key clinical or exclusivity windows, or deploy a modest call spread (debit) to play upside from successful phase-3 data with defined loss equal to premium. Aim for 3:1 upside potential vs premium paid on successful readouts; abandon if pipeline milestone slips >30 days.